GO
Loading...

Cubist Pharmaceuticals Inc

More

  • FDA OKs Cubist antibiotic for serious infections Friday, 19 Dec 2014 | 6:34 PM ET

    TRENTON, N.J.— The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May. The approval of Zerbaxa on Friday is the second antibiotic approval this year for Cubist Pharmaceuticals, a drugmaker focused on antibiotics. It is being acquired for...

  • Dec 17- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck& co Inc's ertapenem in a late-stage study. Tetraphase is also testing the drug against Johnson& Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...

  • Nasdaq stocks posting largest volume increases Tuesday, 9 Dec 2014 | 6:10 PM ET

    ARCA biopharma Inc.: Approximately 2,208,600 shares changed hands, a 869.0 percent increase over its 65- day average volume. The shares rose$. 09 or 12.8 percent to$. 80. Bluebird Bio Inc.: Approximately 5,804,100 shares changed hands, a 1,300.7 percent increase over its 65- day average volume.

  • Merck and Spirit Airlines are big market movers Tuesday, 9 Dec 2014 | 4:43 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Merck& Co., down $1.87 to $60.01. T-Mobile US Inc., down $2.35 to $25.85.

  • Most active Nasdaq-traded stocks Tuesday, 9 Dec 2014 | 1:21 PM ET

    Apple Inc. rose 1.5 percent to $114.12 with 56,967,700 shares traded. Cisco Systems Inc. rose. 7 percent to $27.42 with 25,321,400 shares traded. Cubist Pharmaceuticals Inc. fell 4.7 percent to $95.83 with 22,721,500 shares traded.

  • Merck committed to Cubist after patent losses Tuesday, 9 Dec 2014 | 9:29 AM ET

    Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday. The court upheld one patent that would stave off a cheaper generic version of the drug from rival Hospira Inc. until...

  • Trader on the floor of the New York Stock Exchange.

    Stocks declined Monday as trade numbers from China came in below expectations and oil companies were knocked by the falling price of crude.

  • Cubist options unusually active before Merck deal Monday, 8 Dec 2014 | 12:50 PM ET

    NEW YORK, Dec 8- Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck& Co will buy Cubist for a hefty premium. Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Implied volatility jumped to...

  • NEW YORK, Dec 8- U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity. Major indexes opened slightly lower after data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7...

  • NEW YORK, Dec 8- U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.

  • NEW YORK, Dec 8- U.S. stocks were poised for a lower open on Monday, putting the S&P 500 on track to pull back from its latest record high, as soft data in China and Japan kindled global growth concerns. Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in...

  • NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from its latest record high, as soft data in China and Japan kindled global growth concerns. *Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third...

  • Cubist Pharm's shares soar on BIG Merck deal Monday, 8 Dec 2014 | 7:59 AM ET
    A researcher at a Cubist Pharmaceuticals lab.

    Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.

  • Early movers: CBST, MRK, EBAY, SBUX, INFY & more Monday, 8 Dec 2014 | 7:52 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures fall after soft China, Japan data Monday, 8 Dec 2014 | 7:37 AM ET

    NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from a record high, as soft data in China and Japan stoked global growth concerns. *Merck& Co Inc said it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion. *European shares were lower after the data from China and Japan.

  • Merck in talks to buy Cubist for over $8B Friday, 5 Dec 2014 | 11:51 PM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck is in talks to acquire antibiotics maker Cubist for about $102 a share in cash, according to people familiar with the matter.

  • Cubist Pharma recalls some vials of antibiotic Cubicin Wednesday, 6 Aug 2014 | 8:24 AM ET

    Aug 6- Cubist Pharmaceuticals Inc said it recalled some vials of its antibiotic Cubicin due to the potential presence of glass particles. Cubist said no adverse events had been reported so far. It did not reveal how many lots were affected, but said the issue was limited to one of its suppliers.

  • The R&D elite: America's most innovative companies Wednesday, 6 Aug 2014 | 6:00 AM ET

    The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.